Rev-erb beta/NR1D2 Antibody - BSA Free

Immunocytochemistry/ Immunofluorescence: Rev-erb beta/NR1D2 Antibody [NBP2-56141]

Immunocytochemistry/Immunofluorescence: Rev-erb beta/NR1D2 Antibody [NBP2-56141] - Staining of human cell line PC-3 shows localization to nucleoplasm.

Immunohistochemistry: Rev-erb beta/NR1D2 Antibody [NBP2-56141] -

Immunohistochemistry: Rev-erb beta/NR1D2 Antibody [NBP2-56141] - Cancer cells from small cell carcinoma employ highly divergent regulatory program compared to adenocarcinoma cells.a,b, Gene set expression scores of single G1 cells using expression signature of NEPC18 (a) & set of genes regulated by AR17 (b). Box plots: center line, median; box limits, upper & lower quartiles; whiskers extend at most 1.5× interquartile range past upper & lower quartiles; P values from 2-sided Mann–Whitney U-test. c, Inferred activity of regulons of different transcriptional regulators. x axis, q values from comparison of inferred regulon activity in cancer cells from small cell carcinoma (n = 76) vs cancer cells from adenocarcinomas (n = 188, sampled as described in Methods) (negative values indicate regulon is less active in small cell carcinoma; two-sided Mann–Whitney U-test, median outcome of sampling iterations (Methods) w/ Bonferroni FWER correction). y axis: P values (two-sided Mann–Whitney U-test, signed as previous) from comparison of expression scores of scRNA-derived regulons in bulk RNA-seq of small cell carcinomas (n = 8) vs adenocarcinomas (n = 18) from a published cohort8. d, Regulon activity in single cells for select transcriptional regulators. e, Hierarchical clustering of bulk RNA-seq of a published cohort of prostate cancers of known histopathology18 based on expression of HOXB5, HOXB6 & NR1D2 regulons inferred from scRNA-seq. B–E correspond to different NEPC subtype labels from original publication. Expression levels of EZH2, NANOG & SOX2 shown for reference but not used in clustering (n = 34 adenocarcinoma, 15 NEPC). f, IHC staining of HOXB5, HOXB6 & NR1D2 protein levels in two prostate adenocarcinoma xenografts (LNCaP & VCaP) & four NEPC patient-derived organoids. Scale bar: 50 μm. Image collected & cropped by CiteAb from following publication (https://pubmed.ncbi.nlm.nih.gov/33664492), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Chromatin Immunoprecipitation-exo-Seq: Rev-erb beta/NR1D2 Antibody - BSA Free [NBP2-56141]

ChIP-Exo-Seq composite graph for Anti-NR1D2 (NBP2-56141) tested in K562 cells. Strand-specific reads (blue: forward, red: reverse) and IgG controls (black: forward, grey: reverse) are plotted against the distance from a composite set of reference binding sites. The antibody exhibits robust target enrichment compared to a non-specific IgG control and precisely reveals its structural organization around the binding site. Data generated by Prof. B. F. Pugh´s Lab at Cornell University.